# Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

> **NCT02218177** · — · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 30 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept
- **DRUG:** Ranibizumab
- **PROCEDURE:** Combination Photodynamic Therapy

## Key facts

- **NCT ID:** NCT02218177
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-08
- **Final completion:** 2016-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218177, "Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02218177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*